4Singh H,Reed J,Noble S,et al.United States Iron Sucrose (Venofer) Clinical Trials Group.Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesisstimulating agents for anemia:a randomized,controlled trial.Clin J Am Soc Nephrol,2006,1 (3):475-482.
5Li H,Wang SX.Intravenous iron sucrose in peritoneal dialysis patients with renal anemia.Perit Dial Int,2008,28(2):149-154.
6Aggarwal HK,Tziviskou E,Bellizzi V,et al.Prolonged administration over 6h of large doses of intravenous iron saccharate (500 mg)prevents severe adverse reactions in peritoneal dialysis patients.Perit Dial Int,2002,22(5):636-637.
7National Kidney Foundation:K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Diseasw:update 2000.Am J Kidney Dis,2001,37(1 Suppl 1):s182-s238.
8DeVecchi AF,Novembrino C,Lonati S,et al.Two differentmodalities of iron gluconateiv.Administration:effectson iron,oxidative and inflammatory status in peritoneal dialysis patients.Nephrol Dial Transplant,2007,22(6):1709-1713.
9Chertow GM,Mason PD,Vaage-Nilsen O,et al.Update on adverse drug events associated with parenteral iron.Nephrol Dial Transplant,2006,21 (2):378-382.
10Bailie GR,Johnson CA,Mason NA.Parenteral iron use in the management of anemia in end-stage rena disease patient.Am J Kidney Dis,2000,35 (1):1-12.
